Novartis AG
ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
Last updated:
Abstract:
The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonists for the treatment, amelioration, prevention or delay of progression of fatigue, narcolepsy, excessive daytime sleepiness, nocturnal sleep disturbance, and/or cataplexy.
Status:
Application
Type:
Utility
Filling date:
21 Mar 2022
Issue date:
7 Jul 2022